If the exposure to gonadotoxic treatments occurs in post-pubertal female patients, the potential clinical pictures encompasses either overt premature ovarian failure (POI, defined as the combination of oligo-amenorrhoea and raised FSH in the post-menopausal range in women <40 years), or a milder condition known as diminished ovarian reserve (DOR), a subclinical state defined as retained menses, normal FSH but reduced markers of ovarian reserve (i.e., low anti-Müllerian hormone and reduced antral follicular count on pelvis ultrasound). Here, BRD2 is linked to primary ovarian failure.